Amgen Inc (NASDAQ:AMGN) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6). The study met its primary endpoint of overall survival ...
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic ...
FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a ...
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific ...
Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer DESTINY-Gastric04 will be unblinded at interim analysis based on the superior ...
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) Between October 2019 and June 2021, 32 patients with dMMR/MSI-H gastric/GEJ adenocarcinoma were enrolled. The median age was 65 ...
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone Bemarituzumab plus chemotherapy ...
ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to ...
HUTCHMED (China) Limited has completed patient enrollment for the registration phase of its Phase II trial assessing savolitinib in gastric cancer patients with MET amplification. This multi-center, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results